Abstract
The asymmetric synthesis of the potent selective NOP agonist 2-(3-{1-[3-(5-methoxy-2-methyl-phenoxy)-4-methyl-pentyl]-piperidin-4-yl} -2-oxo-2,3-dihydro-benzimidazol-1-yl)-N-methyl-acetamide and analogues was developed. The key step, chiral reduction of methyl isobutyryl acetate, was achieved using a mild Noyori-type asymmetric hydrogenation. © 2008 Elsevier Ltd. All rights reserved.
| Original language | English |
|---|---|
| Pages (from-to) | 3119-3126 |
| Number of pages | 8 |
| Journal | Tetrahedron |
| Volume | 64 |
| Issue number | 14 |
| DOIs | |
| Publication status | Published - 31 Mar 2008 |
Keywords
- Asymmetric hydrogenation
- Chiral reduction
- NOP/ORL1 agonist
- Noyori catalyst
Fingerprint
Dive into the research topics of 'Asymmetric synthesis of N-3 substituted phenoxypropyl piperidine benzimidazol-2-one derivatives, potent and selective NOP agonists'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver